-
Characterisation of the antibacterial properties of the recombinant phage endolysins AP50-31 and LysB4 as potent bactericidal agents against Bacillus anthracis.
SG Park, SY Jun, CH Kim, GM Jung, JS Son, ST Jeong, SJ Yoon, SY Lee & SH Kang
Scientific Reports, 2018 Jan 8(1)
- Pharmacokinetics and Tolerance of the Phage Endolysin-Based Candidate Drug SAL200 after a Single Intravenous Administration among Healthy
Volunteers.
Jun SY, Jang IJ, Yoon SH, Jang KH, Yu KS, Cho JY, Seong MW, Jung GM, Yoon SJ, Kang SH
Antimicrob Agents Chemother. 2017 May 24;61(6).
-
Evaluating the effectiveness of Streptococcus parauberis bacteriophage Str-PAP-1 as an environmentally friendly alternative to antibiotics for aquaculture
Kwon AS, Kang BJ, Jun SY,Yoon SJ, Lee JH, Kang SH
Aquaculture., 468(Part 1):464-470, 2017
- Pharmacokinetics of the phage endolysin-based candidate drug SAL200 in monkeys and its appropriate intravenous dosing period
Jun SY, Jung GM,
Yoon SJ, Youm SY, Han HY, Lee JH, Kang SH
Clin Exp Pharmacol Physiol., 43(10):1013-1016, 2016
-
Preclinical Safety Evaluation of Intravenously Administered SAL200 Containing the Recombinant Phage Endolysin SAL-1 as a Pharmaceutical Ingredient
Jun SY, Jung GM, Yoon SJ, Choi YJ, Koh WS, Moon KS, Kang SH
Antimicrobial Agents and Chemother., 58(4):2084~2088, 2014
- Antibacterial Properties of a pre-formulated Recombinant Phage Endolysin, SAL-1
Jun SY, Jung KM, Yoon SJ, Oh MD, Choi YJ, Lee WJ, Kong JC, Seol JG, Kang SH
International J. of Antimicrobial Agents, 41:156~161, 2013.
- Comparison of the Antibacterial Properties of Phage Endolysins SAL-1 and LysK
Jun SY, Jung GM, Son JS, Yoon SJ , Choi YJ, and Kang SH
Antimicrobial Agents and Chemother., 55(4):1164~67, 2011
- Complete genome sequence of a newly isolated lytic bacteriophage, EFAP-1 of Enterococcus faecalis, and antibacterial activity of its endolysin EFAL-1
Son JS, Jun SY, Kim EB, Park JE, Paik HR, Yoon SJ, Kang SH, Choi YJ.
J of Applied Micribiol., 108:1769-79, 2010
-
Characterization of Staphylococcus aureus derived from bovine mastitis and isolation of two lytic bacteriophages.
Son JS, Kim EB, Lee SJ, Jun SY, Yoon SJ, Kang SH, Choi YJ.
J of General and Applied Microbiol. 56(4):347-53, 2010
- One-step preparation of a TA-cloning vector from a specially designed parent plasmid containing a dual lacZ gene system.
Jun SY, Yoon SJ, Kang SH
Molecular Biotechnology, 45(1):9-14, 2010
-
Antibacterial and biofilm removal activity of a podoviridae Staphylococcus aureus bacteriophage SAP-2 and a derived recombinant cell-wall-degrading enzyme.
Son JS, Lee SJ, Jun SY, Yoon SJ, Kang SH, Paik HR, Kang JO, Choi YJ.
Appl. Microbiol. Biotechnol., 86:1439-49, 2010
- Anti-tumor effect associated with down-regulation of MHC class I antigen after co-transduction of GM-CSF and IFN-gamma genes in CT26 cells.
Yoon SJ, Lee JC, Kang JO, Lee SG, Heo DS.
Anticancer Res. 21(6A):4031-9, 2001
-
Enhancement of adenoviral transduction with polycationic liposomes in vivo.
Lee SG, Yoon SJ, Kim CD, Lim DS, Sung MW, Yeom YI, Heo DS, and Kim NK.
Cancer Gene Ther., 7(10):1329-1335, 2000
- Development of a new plasmid vector with PSA-promoter and enhancer expressing tissue-specificity in prostate carcinoma cell lines.
Lee SE, Jin RJ, Lee SG, Yoon SJ, Park MS, Heo DS, Choi H.
Anticancer Res. 20(1A):417-22, 2000
-
Effect of GM-CSF and IL-2 co-expression on the anti-tumor immune response.
Yoon SJ, Lee SG, Heo DS, Jee YS, Kang JO, Kim K, Kim CD, Sung MW, and Kim NK.
Anticancer Res., 20(4):2681-2686, 2000
- The expression of MHC class I, TAP1/2 and LMP2/7 gene in human gastric cancer cell lines.
Kang JK, Yoon SJ, Kim NK, Heo DS.
Int J Oncol. 16(6):1159-63, 2000
- Reduced expression of MHC class I antigen in human cancer cell lines with defective LPM-7.
Yoon SJ, Kang JO, Park JS, Kim NK, Heo DS.
Anticancer Res. 20(2A):949-53, 2000
- Cationic liposome-enhanced adenoviral gene transfer in a murine head and neck cancer model.
Sung MW, Lee SG, Yoon SJ, Lee HJ, Heo DS, Kim KH, et al.
Anticancer Res. 20(3A):1653-6, 2000
-
Combination gene therapy of IL-12 and allogenic MHC class I gene via stimulating NK cytolytic activity.
Yoon SJ, Heo DS, Kang JO, Kim NK.
Anticancer Res. 19(5B):4337-42, 1999
- The effect of prostaglandin and its inhibitor on antibody-dependent cellular cytotoxicity against human squamous cell carcinoma of head and neck.
Kim CD, Sung MW, Lee SJ, Heo DS, Yoon SJ, Kim KH.
Anticancer Res. 19(1A):455-9, 1999
- Locoregional response and increased natural killer activity after intratumoral injection of HLA-B7/2-microglobulin gene in patients with cancer.
Heo DS, Yoon SJ, Kim WS, Lee KH, et al.
Int J Oncol. 16(6):1159-63, 2000
- Reduced expression of MHC class I antigen in human cancer cell lines with defective LPM-7.
Yoon SJ, Kang JO, Park JS, Kim NK, Heo DS.
Human Gene Therapy, 9:2031-2038, 1998.
- Synergistic anti-tumor effects with co-expression of GM-CSF and IFN-g in murine tumors.
Yoon SJ, Heo DS, Kang JO, Lee SG, Kim CD, Sung MW, and Kim NK.
Int. J. Cancer, 77:907-912, 1998
-
Isolation and identification of phytase-producing bacterium, Enterobacter sp. 4, & enzymatic properties of phytase enzyme.
Yoon SJ, Choi YJi, Min HK, Cho KK, Kim JW, Lee SC, and Jung YH.
Enzyme & Microbial Technology 18:449- 454, 1996